MiNK Therapeutics reported its third quarter 2026 results, highlighting its first pre-commercial revenue from the cell therapy agenT-797, accessed by patients through a named-patient program. The company is advancing a randomized Phase 2 trial for acute respiratory distress syndrome (ARDS), a condition with high mortality and no approved effective treatments, with U.S. dosing expected before year-end and data anticipated in the second half of 2027. Additionally, MiNK was selected by ARPA-H for a program to develop room-temperature deployable cell therapies, potentially removing the need for cold storage. Financially, MiNK improved its net loss per share by 23% year-over-year and achieved a 44% gain in general and administrative efficiency, while focusing investment on its randomized ARDS trial and leveraging non-dilutive funding for other programs.
MiNK Therapeutics' third quarter 2026 results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: out of 150 priced US health-sector stocks, 67 rose and 75 fell. Notable movers include INO at USD 1.32 with a 10.20% decline, TWST at USD 141.14 with a 6.82% gain, and TNGX at USD 23.00 with a 5.35% drop.
RUM Group Inc. reported a record quarterly revenue of $96.6 million for Q3 2026, a 290% increase year-over-year, surpassing expectations. Despite this, earnings per share were -$0.19, missing the estimate of -$0.11. The company achieved its first pro...
The 2026 Vertex CompOps™ Index reveals that just 16% of enterprises regularly discuss indirect tax at the board level, while 43% only address it when issues arise. Companies with board-level focus on indirect tax are four times less likely to have er...
Richtech Robotics announced its Intelligent Cleaning System at ISSA Show North America 2026, which integrates autonomous cleaning robots with CCTV cameras to enable proactive, targeted cleaning. This system uses real-time data to optimize cleaning ta...
Blue Gold Limited is reducing operating costs and restructuring its balance sheet to address financial obligations and comply with Nasdaq listing requirements. The company is cutting headcount, streamlining operations, and exploring creditor arrangem...
Longevity Health Holdings announced its Board is exploring strategic alternatives for its bio-aesthetic and therapeutic businesses to maximize stakeholder value. Options under consideration include mergers, sales, licensing, or partnerships. This mov...
